Caldera Therapeutics Launches with $112.5 Million to Advance Bispecific Antibody for IBD

Leila Ahmed North America Legal Chronicle
Tagged:

Fenwick & West has advised Caldera Therapeutics. Caldera Therapeutics, a clinical-stage biotechnology company, has secured $112.5 million in funding to support the development of its bispecific…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Leila Ahmed

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here